AAV manufacturing and other types of advanced therapy production are experiencing challenges associated with their plasmid DNA supply. This includes slow or delayed production and poor DNA quality (owing to unstable or difficult sequences), impacting their ability to meet drug development timelines and regulatory demands.
In this webinar, the featured speakers will address the challenges of plasmid DNA in AAV manufacturing and present data and supportive case studies which introduce an alternative to plasmid DNA — an enzymatic, antibiotic-free DNA vector called doggybone DNA (dbDNA™).
Register to learn how doggybone DNA can eliminate many issues around complex or unstable sequences in AAV production, alongside improved speed to manufacture, safety and scalability.
Dr. Lisa Caproni, Head of Vaccine Therapy, Touchlight
Dr Lisa Caproni was educated at the University of Edinburgh where she completed a BSc and PhD in the area of infectious diseases with her doctoral research focussing on the virulence of the nosocomial pathogen Clostridium difficile. Post-doctoral studies followed in the field of recombinant vaccines, identifying and testing candidate antigens against the zoonotic pathogen Salmonella enterica serovar Typhimurium. This experience facilitated a move into industry to join the vaccine development company Emergent Biosolutions in 2007 working on expanding the utility of the live attenuated Salmonella enterica serovar Typhi vaccine strain through the introduction of heterologous antigens to create dual-target vaccines.
In 2009 Lisa joined the newly founded Touchlight Genetics Ltd where she leveraged her molecular biology and preclinical experience to help the company establish and consolidate its core patent portfolio in the production and applications of doggyboneÔ closed linear DNA. Dr Caproni leads the Vaccine team within Touchlight steering internal research and external relationships within academia and industry. These efforts have led to the current pipeline of prophylactic and therapeutic vaccines in addition to discovery efforts into the use and impact of dbDNAÔ in multiple application areas.Message Presenter
Dr. Leszek Lisowski, Unit Head, Children's Medical Research Institute, University of Sydney
Associate Professor Lisowski is a mid-career researcher with research interest is in genetic engineering of viral vectors, vector manufacturing and genome engineering for use in gene therapy approaches. He received his PhD from Weill Cornell University in New York for studies related to the development of lentiviral vectors for the treatment of β-thalassemia and completed postdoctoral training at Stanford University where he mastered recombinant of adeno-associated virus vector (rAAV) vector design, production, and evolution via multispecies interbreeding. He developed the first bioengineered rAAV to enter clinical evaluation. In 2012 A/Prof. Lisowski was recruited by the Salk Institute for Biological Studies and subsequently in 2015 he was recruited by the University of Sydney / Children’s Medical Research Institute (CMRI) to establish his independent research team, Translational Vectorology Research Unit and to establish and manage Vector and Genome Engineering Facility (VGEF).
His research concentrates on the studies of liver and CNS biology, AAV biology and vectorology, development of novel bioengineered AAV variants. In addition, his group specializes also in development and improvement of viral vector manufacturing technologies, including upstream production and downstream purification, with special interest in clinical vector manufacturing. Currently, together with the NSW Government and key decision makers at the Westmead Research Precinct, A/Prof. Lisowski is building a dedicated clinical vector manufacturing facility. This facility is a critical final component of an Advanced Therapeutics Translational Program (ATTP) established by A/Prof. Lisowski in close collaboration with, and support from, local researchers, clinicians and Precinct Leadership, and it specializes in the development and clinical implementation of gene therapies for paediatric and adult disorders.Message Presenter
Who Should Attend?
Companies working on genetic medicine and key decision makers for process development or new technology evaluation for:
Job roles include:
- Gene therapy professionals
- Scientists working within viral vector manufacturing
- Process Development Scientists
- VPs and Leaders of Scientific Operations
- CEO, CSO in biotech
- CMC Leaders
- Research Scientists
- Product Managers
What You Will Learn
- Discover an alternative to plasmid DNA — an enzymatic, antibiotic-free DNA vector
- Learn how doggybone DNA can eliminate many of the current issues associated with plasmid DNA and accelerate development timelines
- Hear about case studies and data featuring doggybone DNA applied to AAV
Touchlight is a privately-owned company based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced novel DNA formats, such as doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API.
dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.